Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  NASDAQ OMX COPENHAGEN  >  Novo Nordisk A/S    NOVO B   DK0060534915

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq Omx Copenhagen
05/17/2017 05/18/2017 05/19/2017 05/22/2017 05/23/2017 Date
269.2(c) 270.8(c) 272.4(c) 277.1(c) 277.3 Last
3 547 586 3 460 450 2 364 812 3 910 414 3 550 294 Volume
-2.07% +0.59% +0.59% +1.73% +0.07% Change
More quotes
Financials ( DKK)
Sales 2017 116 123 M
EBIT 2017 50 775 M
Net income 2017 38 089 M
Finance 2017 17 014 M
Yield 2017 2,80%
Sales 2018 121 606 M
EBIT 2018 51 818 M
Net income 2018 41 015 M
Finance 2018 16 280 M
Yield 2018 3,05%
P/E ratio 2017 18,02
P/E ratio 2018 16,33
EV / Sales2017 4,54x
EV / Sales2018 4,34x
Capitalization 543 826 M
More Financials
Company
Novo Nordisk AS engages in the research, development, manufacture, and marketing of pharmaceutical products.It operates through the Diabetes and Obesity Care, and Biopharmaceuticals segments.The Diabetes and Obesity Care segment covers insulins, glucagon-like-peptide 1, other protein-related... 
Sector
Pharmaceuticals
Calendar
05/23Presentation
More about the company
Surperformance© ratings of Novo Nordisk A/S
Trading Rating : Investor Rating :
More Ratings
Latest news on NOVO NORDISK A/S
05/22 NOVO NORDISK A/S : Health and Human Services Department (HHS); Food and Drug Adm..
05/22 NOVO NORDISK A/S : Boost as drugs supplier gets Sh12m cold room
05/22 NOVO NORDISK A/S : Mission for Essential Drugs sets up Sh12m cold room for diabe..
05/17 NOVO NORDISK A/S : When diabetes and pro cycling meet
05/17 NOVO NORDISK A/S : Early response to Saxenda® resulted in weight maintenance and..
05/16 NOVO NORDISK A/S : DONG Energy - Historical partnership saves the climate from 2..
05/16 NOVO NORDISK A/S : Novelion CEO quits Novo Nordisk board due to NASH conflict
05/16 NOVO NORDISK A/S : Change in composition of the Board of Directors of Novo Nordi..
05/15 NOVO NORDISK A/S : - Share repurchase programme
05/11 NOVO NORDISK A/S : Launches Xultophy® 100/3.6 insulin degludec and liraglutide i..
More news
Sector news : Pharmaceuticals - NEC
08:35aDJASTRAZENECA : Says Bydureon Trial Meets Safety Objectives; No Significant CV Red..
05/22 Cross-border M&A between U.S. and European firms at 10 year high
05/22DJASTRAZENECA : in Pact with Recordati for Heart-Drug Seloken in Europe
05/19 European shares claw back gains after worst week in six months
05/19 FTSE climbs for fourth straight week, shrugging off Trump slump
More sector news : Pharmaceuticals - NEC
Latest Tweets
10:40aNovo Nordisk preps Saxenda sales drive in Latin America after its 'phenomenal..
1
12:40aMirae Asset Global Investments Co. Ltd. Takes Position in Novo Nordisk A/S $N.. 
12:30aNovo Nordisk preps Saxenda sales drive in Latin America after its 'phenomenal..
1
12:15aNovo Nordisk looks to expand Latin American obesity business
3
05/22Novo Nordisk looks to expand Latin American obesity business  
More tweets
Qtime:52
News from SeekingAlpha
05/15 April Income Update
05/13 THE OBESITY EPIDEMIC : Are Roche And Bristol-Myers Sitting On A Mighty Prospect?
05/11 KEYTRUDA GETS HOT AND PROPELS MERCK : Analysis
05/11 Global Blood perks up 4% after Novo CEO declines comment about potential deal
05/09 When Life Throws You A Curveball
Advertisement
Chart NOVO NORDISK A/S
Duration : Period :
Novo Nordisk A/S Technical Analysis Chart | NOVO B | DK0060534915 | 4-Traders
Full-screen chart
Technical analysis trends NOVO NORDISK A/S
Short TermMid-TermLong Term
TrendsBullishBullishBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 32
Average target price 282  DKK
Spread / Average Target 1,9%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Lars Fruergaard Jørgensen President & Chief Executive Officer
Göran Albert Ando Chairman
Jesper Brandgaard Chief Financial Officer & Executive Vice President
Mads Krogsgaard Thomsen Chief Science Officer & Executive Vice President
Mads Krogsgaard Chief Science Officer
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
NOVO NORDISK A/S6.95%82 171
JOHNSON & JOHNSON10.23%342 817
ROCHE HOLDING LTD.14.79%237 610
NOVARTIS AG6.28%213 719
PFIZER INC.-1.11%191 279
MERCK & CO., INC.8.78%175 160
More Results